Abstract: The invention relates to a process for culturing IL-18BP expressing mammalian cells under serum-free conditions.

Abstract: Provided are compositions of cladribine and cyclodextrin which are especially suited for the oral administration of cladribine.

Abstract: A method is described for a method for the regioselective liquid-phase pegylation of GRF, which increases the yield of the GRF-PEG conjugate having 1 PEG molecule covalently bound to the e-amino group of Lys12. This method is characterized in that the reaction is carried out in a structuring solvent, such as trifluorethanol.

Abstract: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.

Abstract: This invention relates to the novel protein, termed INSP (179), herein identified as a secreted protein, in particular as a member of the leucine rich repeat containing protein family and to the use of this protein and nucleic acid sequences from the encoding gene in the diagnosis, prevention and treatment of disease.

Abstract: The invention provides a method for purifying recombinant FSH.

Abstract: The present invention. The invention relates to the use of interferon-? (IFN-?) for treating and/or preventing Alzheimer's disease (AD), Creutzfeld-Jakob disease (CJD) or Gerstmann-Sträussler-Scheinker disease (GSSD). It further relates to the use of IFN-? in combination with an Alzheimer's disease treating agent for treating and/or preventing Alzheimer's disease. The use of IFN-? in combination with a cholinesterase inhibitor for treating and/or preventing early-onset Alzheimer's disease is preferred.

Abstract: A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON and contains a HSA-free Interferon-? formulation having the following composition: 30 to 100 ?g/ml of interferon-?, an isotonicity agent, 0.1 to 2 mg/ml of Poloxamer 188, at least 0.12 mg/ml of L-Methionine and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0.

Abstract: An improved method of chromatographic analysis of protein samples is disclosed in which a Pluronic surfactant is used.

Abstract: The invention relates to the use of a substance, which binds to and initiates signaling of the human growth hormone (hGH) receptor or a substance, which stimulates release or potentiates the activity of endogenous hGH, for treatment and/or prevention of Parkinsonism-Plus Syndromes. In particular, the invention relates to the use of hGH for the treatment and/or prevention of Multiple System Atrophy.

Abstract: The invention relates to the field of pharmaceutical formulations of a mixture of follicle stimulating hormone (FSH) and luteinising hormone (LH), and to methods of producing such formulations.

Abstract: A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, a surfactant, an isotonicity agent and an antioxidant. Preferably the interferon is human recombinant IFN-beta.

Abstract: The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of TNF-binding protein, comprising a TNF-binding protein, a buffer and an isotonicity agent.

Abstract: The us of an interferon (IFN) for the manufacture of a medicament useful for treatment and/or prevention of Severe Acute Respiratory Syndrome (SARS) is described in the present invention.

Abstract: The invention relates to a liquid formulation comprising a growth hormone or a, substance, which stimulates release or potentiates the activity of endogenous hGH; a polyethylene-polypropylene glycol; a citrate buffer and a stabilizer, and to a process of preparation thereof.

Abstract: The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.

Abstract: A new purification process for Tumor Necrosis Factor-binding proteins is described. In particular this process is characterized by the use as capture step of an Immobilized Metal Affinity Chromatography (IMAC) using copper as metal. This brings advantages in terms of process yields, purity of the final product and applicability to industrial scale.

Abstract: The present invention relates to novel proteins, termed INSP081, INSP082, and INSP091, herein identified as members of the Germinal Center Kinase (GCK) subfamily of the STE20 family of protein kinases, preferably as NCK-interacting kinases (NIKs) and more preferably as NIK-like embryo specific kinases (NESKs), and to the use of these and nucleic acid sequences from the encoding genes in the diagnosis, prevention, and treatment of disease.

Abstract: The invention relates to the use of an agent having, stimulating or maintaining tumor necrosis factor (TNF) activity, together with an interferon (IFN) for treating and/or preventing demyelinating diseases, in particular multiple sclerosis (MS). The use of a combination of a TNF or a tumor necrosis factor binding protein in combination with an interferon for treating and/or preventing demyelinating diseases is preferred.

Abstract: The connecting end of the hypodermic needle is so designed that it can be attached to and then disconnected from the tip of an injection instrument by pressure, that is, an axial tractional force exerted between the said needle and the said injection instrument. The extraction device has an opening delimited by locking elements forming one piece with elastic pieces so as to allow its diameter to vary between a minimum diameter and a maximum diameter at least equal to the diameter of the said connecting end and at least one piece associated with the said locking elements for the purpose of converting an axial force exerted on the said piece into at least one radial component capable of being applied to the said elastic pieces so as to deform them radially in order to increase the diameter of the said opening when axial pressure is exerted by the said connecting end.